1-3 of 3
Jerry Zeldis, MD
Close
Sort by
Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD
Journal: Blood
Blood (2007) 110 (11): 2562.
https://doi.org/10.1182/blood.V110.11.2562.2562
Published: 2007
Journal Articles

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Anfan Wu, PhD, Alan List, MD, Richard Lush, MD, Kelly Bretz, BS, Robert Knight, MD, Jerry Zeldis, MD, Henry Lau, PhD
Journal: Blood
Blood (2006) 108 (11): 4854.
https://doi.org/10.1182/blood.V108.11.4854.4854
Published: 2006
Journal Articles

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

Ashrof Z. Badros, MD, Olga Goloubeva, PhD, Bashi Ratterree, RN, Sabrina Natt, RN, Aaron Rapoport, MD, Javier Bolaños-Meade, MD, Ben Zhang, PhD, Jerry Zeldis, MD, PhD, Stanley Frankel, MD, Barry Meisenberg, MD, James Zwiebel, MD, J. Flaws, PhD, D. Tomic, PhD, Robert Fenton, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 2400.
https://doi.org/10.1182/blood.V104.11.2400.2400
Published: 2004